FDA-approved daraxonrasib targets RAS, a key cancer pathway, and improves survival vs chemotherapy in previously treated pancreatic cancer.
How Could FDA-Approved Daraxonrasib Change Pancreatic Cancer Treatment?
FDA-approved daraxonrasib targets RAS, a key cancer pathway, and improves survival vs chemotherapy in previously treated pancreatic cancer.